Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312295593> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4312295593 endingPage "65" @default.
- W4312295593 startingPage "56" @default.
- W4312295593 abstract "One of the biggest causes of vision loss in the globe is diabetic retinopathy (DR), a consequence of diabetes. Despite significant attempts to lower the prevalence of vision impairment, DR continues to grow. There is damage to the vascular endothelial cells as the first pathophysiology of DRcells and a decrease in pericytes. As a result of the hypoxic reactions that follow, vascular endothelialvascular endothelial growth factor (VEGF) The most effective treatment available right nowControlling blood sugar levels is the key to preventing diabetic retinopathy and diabetic macular edema (DME). Superior in every way Laser therapy, anti-VEGF therapy, steroid therapy, and vitrectomy are all necessary treatments in these situations. Photocoagulation of the retinal pigment epithelium There is strong evidence that non-proliferative diabetic retinopathy (NPDR) is a viable treatment option.results that can be used to keep DR from progressing further. Furthermore, laser therapy has proven to be effective.For example, grid and subthreshold diode laser micropulse photocoagulation (SDM) for DME has been used.reported. In cases of vitreous hemorrhage or tractional retinal detachment in PDR patients, vitrectomy has been undertaken. There has also been significant interest in the ability of anti-VEGF medication to slow the progression of PDR from DME patients. Even with these therapies, many individuals with DR are still at risk of losing their eyesight and developing potentially dangerous side effects.. In the most advanced stages of DR, laser photocoagulation and vitrectomy are effective treatments for preventing severe vision loss. Both approaches, however, have their limitations. Evidence from preclinical and clinical studies shows that targeting renin-angiotensin system inhibition, vascular endothelial growth factor, and renin-angiotensin system blockade can reduce cardiovascular disease risk.the growth hormone, corticosteroids and protein kinase C.DR may be treated with these methodsMethodsThe study between January 2017 and November 2020 total number of patients 2968, Retrospective three year analysis.ResultsIncidence of referable retinopathy was independently associated with known duration of diabetes, age at diagnosis, and use of insulin treatment. For participants needing insulin treatment with a duration of diabetes of 10 years or more, cumulative incidence of referable retinopathy at one and three years was 9.61 and 30.99 per 1000 people, respectively." @default.
- W4312295593 created "2023-01-04" @default.
- W4312295593 creator A5022463784 @default.
- W4312295593 creator A5075372624 @default.
- W4312295593 creator A5084478141 @default.
- W4312295593 date "2022-06-15" @default.
- W4312295593 modified "2023-10-07" @default.
- W4312295593 title "INCIDENCE AND UPDATES MANAGEMENT OF DIABETIC RETINOPATHY" @default.
- W4312295593 doi "https://doi.org/10.56981/m0000227" @default.
- W4312295593 hasPublicationYear "2022" @default.
- W4312295593 type Work @default.
- W4312295593 citedByCount "0" @default.
- W4312295593 crossrefType "journal-article" @default.
- W4312295593 hasAuthorship W4312295593A5022463784 @default.
- W4312295593 hasAuthorship W4312295593A5075372624 @default.
- W4312295593 hasAuthorship W4312295593A5084478141 @default.
- W4312295593 hasBestOaLocation W43122955931 @default.
- W4312295593 hasConcept C118487528 @default.
- W4312295593 hasConcept C134018914 @default.
- W4312295593 hasConcept C141071460 @default.
- W4312295593 hasConcept C2775955145 @default.
- W4312295593 hasConcept C2777104736 @default.
- W4312295593 hasConcept C2778257484 @default.
- W4312295593 hasConcept C2778313320 @default.
- W4312295593 hasConcept C2779829184 @default.
- W4312295593 hasConcept C2780827179 @default.
- W4312295593 hasConcept C2781242345 @default.
- W4312295593 hasConcept C52237779 @default.
- W4312295593 hasConcept C555293320 @default.
- W4312295593 hasConcept C71924100 @default.
- W4312295593 hasConceptScore W4312295593C118487528 @default.
- W4312295593 hasConceptScore W4312295593C134018914 @default.
- W4312295593 hasConceptScore W4312295593C141071460 @default.
- W4312295593 hasConceptScore W4312295593C2775955145 @default.
- W4312295593 hasConceptScore W4312295593C2777104736 @default.
- W4312295593 hasConceptScore W4312295593C2778257484 @default.
- W4312295593 hasConceptScore W4312295593C2778313320 @default.
- W4312295593 hasConceptScore W4312295593C2779829184 @default.
- W4312295593 hasConceptScore W4312295593C2780827179 @default.
- W4312295593 hasConceptScore W4312295593C2781242345 @default.
- W4312295593 hasConceptScore W4312295593C52237779 @default.
- W4312295593 hasConceptScore W4312295593C555293320 @default.
- W4312295593 hasConceptScore W4312295593C71924100 @default.
- W4312295593 hasIssue "2" @default.
- W4312295593 hasLocation W43122955931 @default.
- W4312295593 hasOpenAccess W4312295593 @default.
- W4312295593 hasPrimaryLocation W43122955931 @default.
- W4312295593 hasRelatedWork W1518569938 @default.
- W4312295593 hasRelatedWork W2362336391 @default.
- W4312295593 hasRelatedWork W2370512776 @default.
- W4312295593 hasRelatedWork W2383458307 @default.
- W4312295593 hasRelatedWork W2396472574 @default.
- W4312295593 hasRelatedWork W2460531224 @default.
- W4312295593 hasRelatedWork W3031558567 @default.
- W4312295593 hasRelatedWork W3032752007 @default.
- W4312295593 hasRelatedWork W4302312136 @default.
- W4312295593 hasRelatedWork W3030377562 @default.
- W4312295593 hasVolume "2" @default.
- W4312295593 isParatext "false" @default.
- W4312295593 isRetracted "false" @default.
- W4312295593 workType "article" @default.